Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 15/20 | 0.39 |
| ▸ | JAK3 | P52333 | 6/20 | 0.38 |
| ▸ | JAK2 | O60674 | 6/20 | 0.35 |
| ▸ | TYK2 | P29597 | 3/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29838697 | 0.86 | JAK3 (0.41) | JAK1JAK3JAK2TYK2PDPK1 | |
| SCHEMBL23458587 | 0.80 | JAK3 (0.39) | JAK1JAK3JAK2TYK2ACACB | |
| SCHEMBL19714981 | 0.79 | JAK1 (0.54) | JAK1JAK3JAK2PDPK1 | |
| SCHEMBL19730139 | 0.77 | L3MBTL1 (0.33) | PDPK1MEN1KMT2A | |
| SCHEMBL29593049 | 0.77 | L3MBTL1 (0.33) | PDPK1MEN1KMT2A | |
| SCHEMBL18026251 | 0.75 | JAK3 (0.36) | JAK1JAK3JAK2TYK2ACACB | |
| SCHEMBL29780438 | 0.74 | JAK1 (0.35) | JAK1JAK3JAK2TYK2ACACB | |
| SCHEMBL23458628 | 0.72 | ACACB (0.35) | JAK1JAK3JAK2TYK2ACACB | |
| SCHEMBL31123773 | 0.72 | BUB1 (0.34) | PDPK1 | |
| SCHEMBL31123801 | 0.72 | BUB1 (0.34) | PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12173026-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-12-24 | — | — | US | disclosed |
| US-20230062119-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME LLC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20220363707-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363707-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | JAK1 2058/4885JAK3 2185/4885JAK2 791/4885 |
| US-12173026-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | JAK1 2058/4885JAK3 2185/4885JAK2 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.